BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34445807)

  • 1. Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.
    Sabbih GO; Danquah MK
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
    Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
    J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy.
    Zhang L; Wang M; Zhu Z; Ding C; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
    Int J Nanomedicine; 2021; 16():3217-3240. PubMed ID: 34007175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
    Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
    Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.
    Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F
    Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disialoganglioside directed immunotherapy of neuroblastoma.
    Modak S; Cheung NK
    Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionalized GD2 Electrochemical Immunosensor to Diagnose Minimum Residual Disease of Bone Marrow in Neuroblastoma Effectively.
    Chen C; Hu C; He B; Bai Y; He F; Li S; Tan CS
    Biosensors (Basel); 2023 Oct; 13(10):. PubMed ID: 37887113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
    Hartomo TB; Kozaki A; Hasegawa D; Van Huyen Pham T; Yamamoto N; Saitoh A; Ishida T; Kawasaki K; Kosaka Y; Ohashi H; Yamamoto T; Morikawa S; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Iijima K; Matsuo M; Nishio H; Nishimura N
    Oncol Rep; 2013 Apr; 29(4):1629-36. PubMed ID: 23417100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma.
    Sha YL; Liu Y; Yang JX; Wang YY; Gong BC; Jin Y; Qu TY; Xia FT; Han L; Zhao Q
    J Exp Clin Cancer Res; 2022 Oct; 41(1):314. PubMed ID: 36284313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico Insights on GD2 : A Potential Target for Pediatric Neuroblastoma.
    Limaye A; Sweta J; Madhavi M; Mudgal U; Mukherjee S; Sharma S; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2019; 19(30):2766-2781. PubMed ID: 31721713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
    Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
    Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
    Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
    Mabe NW; Huang M; Dalton GN; Alexe G; Schaefer DA; Geraghty AC; Robichaud AL; Conway AS; Khalid D; Mader MM; Belk JA; Ross KN; Sheffer M; Linde MH; Ly N; Yao W; Rotiroti MC; Smith BAH; Wernig M; Bertozzi CR; Monje M; Mitsiades CS; Majeti R; Satpathy AT; Stegmaier K; Majzner RG
    Nat Cancer; 2022 Aug; 3(8):976-993. PubMed ID: 35817829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma.
    Su Y; Wang L; Wang X; Yue Z; Xing T; Zhao W; Zhao Q; Duan C; Huang C; Han Y; Qiu L; Cheng X; Liu Y; Ma X
    Cancer Med; 2019 Apr; 8(4):1558-1566. PubMed ID: 30793512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
    Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
    Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
    Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.
    Roth M; Linkowski M; Tarim J; Piperdi S; Sowers R; Geller D; Gill J; Gorlick R
    Cancer; 2014 Feb; 120(4):548-54. PubMed ID: 24166473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.